- Home
- MBIN vs MNKD Comparison
MBIN vs MNKD Comparison
Compare MBIN & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBIN
- MNKD
- Stock Information
- Founded
- MBIN 1990
- MNKD 1991
- Country
- MBIN United States
- MNKD United States
- Employees
- MBIN N/A
- MNKD N/A
- Industry
- MBIN Major Banks
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- MBIN Finance
- MNKD Health Care
- Exchange
- MBIN Nasdaq
- MNKD Nasdaq
- Market Cap
- MBIN 2.0B
- MNKD 1.6B
- IPO Year
- MBIN 2017
- MNKD 2004
- Fundamental
- Price
- MBIN $36.84
- MNKD $4.98
- Analyst Decision
- MBIN Buy
- MNKD Buy
- Analyst Count
- MBIN 3
- MNKD 6
- Target Price
- MBIN $51.50
- MNKD $8.92
- AVG Volume (30 Days)
- MBIN 151.7K
- MNKD 2.0M
- Earning Date
- MBIN 04-28-2025
- MNKD 05-07-2025
- Dividend Yield
- MBIN 1.09%
- MNKD N/A
- EPS Growth
- MBIN 11.70
- MNKD N/A
- EPS
- MBIN 6.30
- MNKD 0.10
- Revenue
- MBIN $646,454,000.00
- MNKD $285,504,000.00
- Revenue This Year
- MBIN $9.52
- MNKD $14.66
- Revenue Next Year
- MBIN $5.69
- MNKD $14.27
- P/E Ratio
- MBIN $5.87
- MNKD $49.50
- Revenue Growth
- MBIN 23.72
- MNKD 43.50
- 52 Week Low
- MBIN $34.16
- MNKD $3.97
- 52 Week High
- MBIN $53.27
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- MBIN 36.84
- MNKD 36.48
- Support Level
- MBIN $36.22
- MNKD $4.89
- Resistance Level
- MBIN $38.39
- MNKD $5.12
- Average True Range (ATR)
- MBIN 1.25
- MNKD 0.13
- MACD
- MBIN -0.06
- MNKD 0.00
- Stochastic Oscillator
- MBIN 24.44
- MNKD 21.82
About MBIN Merchants Bancorp
Merchants Bancorp is a United States based bank holding company. It operates multiple lines of business focusing on FHA (Federal Housing Administration) multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, traditional community banking. The business segments of the company are: Multi-family Mortgage Banking which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing segment which funds agency-eligible residential loans as well as commercial loans to nondepository financial institutions; and Banking segment that provides a wide range of financial products and services to consumers and businesses, including commercial and other consumer loan products.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.